Your exclusive offer / Product highlight Goes Here

20% off

Season Sale

Free Shipping

On Orders over $99

easy returns

24/7 support

Online chat available

Vitae America

Brain HEALTH Technology

​Vitae ​America

Brain HEALTH Technology

​Vitae ​America

Brain HEALTH Technology

​The Value of Prevention


​Just one little word produces an almost visceral reaction. It conjures images and thoughts of loss of self, loss of mind, loss of control, and the burden of care placed on family members and loved ones.

In 2018, the estimated cost of caring for Americans with Alzheimer’s and other dementias was $277 billion – and that doesn’t include unpaid caregiving.

The toll of Alzheimer’s Disease is staggering!

​​These are the facts:

  • ​Every 65 seconds someone in the United States develops Alzheimer’s disease.
  • 5.8 MILLION Americans are living with Alzheimer’s.  By 2050, this number is project to rise to nearly 14 MILLION.
  • 18.5 BILLION hours of care, valued at nearly $234 BILLION, are provided by family and other unpaid caregivers.
  • In 2019, Alzheimer’s and other dementias will cost the nation $290 BILLION. By 2050, these costs could rise as high as $1.1 TRILLION.
  • Alzheimer’s disease is the 6TH LEADING cause of death in the United States.  1 in 3 seniors dies with Alzheimer’s or another dementia. It kills more than breast cancer and prostate cancer combined.
  • Between 2000 and 2017 deaths from heart disease have decreased 9% while deaths from Alzheimer’s have increased 145%. (“2019 Alzheimer’s Disease Facts,” 2019)

​These staggering numbers are just for the United States.

The worldwide devastation from this disease is even more profound.  According to a 2007 paper published by Johns Hopkins University, Forecasting the Global Burden of Alzheimer’s Disease, the authors estimate that by 2050 the prevalence of the disease will quadruple and approximately 1 in 85 people will be affected (Brookmeyer, 1).  Based on that research, the World Population Clock, and Population Reference Bureau estimates for 2050, the number affected would be approximately 116.5 million people.  Alzheimer’s Disease International paints an even more alarming picture.  According to their estimates by 2030, 74.7 million will be affected and by 2050 that number reaches 131.5 million.  The hardest hit will be those in low and middle income countries (“Dementia Statistics,” n.d.).

The bright spot for those dealing with the disease is that research is ongoing.  There are several drugs in the pipeline that are showing some good results. There is optimism that these will continue on that trajectory and will be available.  The downside to these new drugs is the side effects.

At the same time pharmaceuticals are being developed, researchers are also looking at more natural paths to stem the onslaught of the disease. Scientists are studying the gut, the microbiome, and the whole gut-liver-brain axis for how these all interconnect to Alzheimer’s disease and the broader dementia spectrum.  Researchers are investigating, “how the digestive system, including gut and liver functions, may be related to changes in the brain and AD” (Giordani, 75).  It is already established that issues with the microbiome are tied to inflammation and autoimmune conditions which are associated with Alzheimer’s disease.  Further, it’s being demonstrated that dietary changes affecting the gut bacteria can affect brain health (Giordani, 74-75, Ticinesi, 1497).

​Introducing Plasmalogen

​Of the myriad of compounds that make up living organisms, one that was discovered in 1924 is actively being investigated and is being shown to be a powerhouse.  Plasmalogens are lipid compounds found in various human and mammalian tissues that was found to have higher concentrations in the brain, cardiovascular, nervous, and immune systems and in human heart tissue.  While they were discovered long ago it is only fairly recently that science is discovering the connections between these compounds and health and disease.  Research into decreases in plasmalogen is yielding results.  Several studies, (Wood, 2010, 2012, & 2015, Goodenowe, 2007, Yamashita, 2016) while focusing on Alzheimer’s disease, highlight the fact that plasmalogen concentration may serve as an important biomarker to allow early detection of several diseases.  A 2012 study revealed that the brain contains the highest amount of tissue plasmalogens and that a decrease in the concentration of these can be shown in numerous neurodegenerative disorders including Alzheimer’s, Parkinson’s and even Down syndrome (Braverman, 1442).  As a result of this research, better tests could be developed that would make early detection possible and allow quicker interventions that could improve clinical outcomes.

Some of the most exciting research into Plasmalogens is leading to some potential interventions for those suffering with Alzheimer’s and other dementia spectrum diseases.  A study published in 2019, documented, “positive therapeutic outcomes” for both Alzheimer’s disease subjects and rodents using orally administered plasmalogen supplements (Su, 1).  Studies in 2012 and 2017 (Fujino and Mawatari) showed statistically significant outcomes with little to no adverse effects.  While further research about the therapeutic benefits of plasmalogens in humans is needed the research so far is positive.  Good news for those wanting a more natural approach to fighting this terrible disease.  


2019 Alzheimer’s Disease Facts and Figures. (2019). Retrieved from, N. E., Moser, A. B. (2012). Functions of plasmalogen lipids in health and disease. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 1822(9):1442-1452. doi: 10.1016/j.bbadis.2012.05.008, R., Johnson, E., Ziegler-Graham, K., Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer’s disease. The Berkeley Electronic Press. (Paper 130). 1 – 20. statistics. Alzheimer’s Disease International. Retrieved from, T., Yamada, T., Asada, T., Tsuboi, Y., Wakana, C., Mawatari, S., & Kono, S. (2017). Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer’s disease and mild cognitive impairment: A multicenter, randomized, double-blind, placebo-controlled trial. EBioMedicine, 17, 199–205. doi:10.1016/j.ebiom.2017.02.012Giordani, B. (2018). The latest in Alzheimer’s disease research: 2018. Retrieved from, D. B., Cook, L. L., Liu, J., Lu, Y., Jayasinghe, D. A., Ahiahonu, P. W., Heath, D, Yamazaki Y, Flax, J., Krenitsky, K. F. (2007).  Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer’s disease and dementia. Journal of Lipid Research. 48:2485–98.Mawatari, S., Katafuchi, T., Miake, K., & Fujino, T. (2012). Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Lipids in Health and Disease, 11, 161. doi:10.1186/1476-511X-11-161Su, X. Q., Wang, J., & Sinclair, A. J. (2019). Plasmalogens and Alzheimer’s disease: a review. Lipids in Health and Disease, 18(1), 100., A., Tana, C., Nouvenne, A., Prati, B., Lauretani, F., & Meschi, T. (2018). Gut microbiota, cognitive frailty and dementia in older individuals: A systematic review. Clinical Interventions in Aging, 13, 1497–1511. doi:10.2147/CIA.S139163Wood, P. L., Mankidy, R., Ritchie, S., Heath, D., Wood, J. A., Flax, J., & Goodenowe, D. B. (2010). Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. Journal of Psychiatry & Neuroscience : JPN, 35(1), 59–62. doi:10.1503/jpn.090059Wood P. L. (2012). Lipidomics of Alzheimer’s disease: Current status. Alzheimer’s Research & Therapy, 4(1), 5. doi:10.1186/alzrt103Wood, P. L., Barnette, B. L., Kaye, J. A., Quinn, J. F., Woltjer, R. L. (2015). Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer’s disease subjects. Acta Neuropsychiatry. 2015;27:270–8.Yamashita, S., Kiko, T., Fujiwara, H., Hashimoto, M., Nakagawa, K., Kinoshita, M., Furukawa, K., Arai, H., Miyazawa, T. (2016). Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer’s disease: possible interactions between amyloid-β and these lipids. Journal of Alzheimer’s Disease; 50(2):527-37. doi: 10.3233/JAD-150640

​Other Articles

​Truly Regenerative Properties

Plasmalogen, the break-through molecule in our flagship product, has shown extraordinary potential to preserve and regain cognitive function. Discover the groundbreaking power of Plasmalogen today!

​The Best Source of Plasmalogen

​​Japanese Sea Squirt, also known as Japanese Pineapple, is the premiere source of Plasmalogen. Beyond having rich plasmalogen levels, Sea Squirt is packed with important minerals as well as EPA/DHA.

Clinical Research

plasmalogen lipids in health and disease

In this article, researchers from McGill University in Montreal and John Hopkins Hospital in Baltimore explore the novel properties of Plasmalogens and their role in physiology. It highlights structural attributes while exploring the Plasmalogen deficiency in disease states.

Read the full article now



This article from Mayo Foundation Clinic and Boston University School of Medicine highlights the role of Plasmalogens in nervous tissue and throughout important areas of the human body.

Read the full article now



A team of researchers in Germany explore the ether lipid-deficient mouse. Highlighting the functions related to cell–cell or cell–extracellular matrix interactions, formation of lipid raft microdomains and intracellular cholesterol homeostasis, this article focuses on the role of Plasmalogens in disease.

Read the full article now


Plasmalogen Researched Benefits

Powerful Antioxidant

Because it has a vinyl ether bond, having high reactivity with oxygen​, ​​it is considered to play the role of antioxidant.

Learning and Memory

Learning and memory ability of Alzheimer’s rats fed ​Plasmalogen recovered after treatment. ​Clinical trials showed improved memory.

Inflammation Suppressant

Protecting the brain from oxidative stress, the unique chemical structure of ​Plasmalogen is a built-in shield from dangerous free radicals.


​Mental Clarity

​Plasmalogen supplementation has shown increases in MMSE score as well as improved scores in surveys in clinical trials.


Copyright 2019, Vitae Corp US – Disclaimer

Showing the single result

We offer secure payment

We accept the following payment methods:

Return Policy

We've updated our return policy


Call Us Here: